FDA Approves Eli Lilly’s Onswik for Once-Weekly Type 2 Diabetes Treatment

The U.S. Food and Drug Administration has approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. The approval, granted on September 24, 2026, provides a new treatment option for patients who currently manage their condition through daily injections.

"For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide. Delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health.

Reducing Treatment Burden

Onswik is intended for use as an adjunct to diet and exercise. By shifting the dosing schedule to once weekly, the medication reduces the patient injection burden by more than 300 injections per year compared to standard once-daily basal insulin regimens. This reduction addresses a primary challenge in patient adherence for chronic diabetes management.

Clinical Basis and Availability

The regulatory approval follows data from the QWINT Phase 3 clinical trial program, which evaluated the efficacy and safety of the weekly insulin against daily alternatives. According to the company's announcement, the drug will be available in the United States in the coming months. It will be offered in two concentrations: 500 units/mL and 1,000 units/mL.

Impact on Diabetes Management

For patients with type 2 diabetes, the transition from daily to weekly basal insulin changes the standard of care. The potential for improved quality of life through reduced injection frequency is a focus for providers looking to simplify treatment plans. As the drug enters the market, its adoption will be measured by its ability to maintain glycemic control comparable to established daily insulin therapies while improving patient compliance.